Possible Consequences of a Shortage of Hydroxychloroquine for Patients with Systemic Lupus Erythematosus amid the COVID-19 Pandemic.

Peschken, Christine A

Peschken, Christine A.

Peschken CA; University of Manitoba Arthritis Centre, Rady Faculty of Health Sciences, Winnipeg, Manitoba, Canada. christine.peschken@umanitoba.ca.

J Rheumatol ; 47(6): 787-790, 2020 06 01.

Article in English | MEDLINE | ID: covidwho-213645

Subject(s)

Coronavirus Infections/drug therapy; Hydroxychloroquine/supply & distribution; Hydroxychloroquine/therapeutic use; Lupus Erythematosus, Systemic/drug therapy; Pandemics/statistics & numerical data; Pneumonia, Viral/drug therapy; Betacoronavirus; COVID-19; Coronavirus Infections/epidemiology; Female; Humans; Lupus Erythematosus, Systemic/diagnosis; Lupus Erythematosus, Systemic/epidemiology; Male; Pandemics/prevention & control; Pneumonia, Viral/epidemiology; Risk Assessment; SARS-CoV-2; United States

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Pandemics / Hydroxychloroquine / Lupus Erythematosus, Systemic Type of study: Diagnostic study / Observational study / Prognostic study Limits: Female / Humans / Male Country/Region as subject: North America Language: English Journal: J Rheumatol Year: 2020 Document Type: Article Affiliation country: Jrheum.200395

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google